-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Teleflex delivered Q1 2026 results with revenue of $548.3M (+32.3% Y/Y), $11M above the consensus, though pro forma adjusted constant currency growth of 5.1% reflects underlying momentum. Adjusted EPS of $1.39 met the consensus but declined from $1.44 the prior year, with significant margin compression as adjusted gross margin fell 470 bps to 61.4% due to tariffs, quality charges, and BIOTRONIK integration. Portfolio transformation shows mixed segment results, with Surgical leading at 9.9% pro forma growth while Interventional faced integration challenges at 3.0% growth. Management maintained full-year 2026 adjusted EPS guidance of $6.25-$6.55, incorporating $90M in stranded costs from divestitures. The company announced a new CEO, Jason Weidman, effective June 8, bringing 25+ years medical device experience as the company focuses on its portfolio optimization plans. We expect the $90M stranded costs fully offset by transition services beginning 2027, providing clearer standalone financial visibility.